Oncology Peer Review On-The-Go: 1-on-1 with David Johnson: Enveric’s Endocannabinoid Products for Glioblastoma


CancerNetwork®’s podcast features an interview with the chairman and CEO of Enveric Biosciences, David Johnson, to discuss the latest in their development of endocannabinoid products.

In this episode, CancerNetwork® sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson thoroughly discussed the background of the biosciences company and detailed the endocannabinoid products Enveric is developing to positively impact quality of life for patients with glioblastoma and other cancers.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast anywhere podcasts are available.

Related Videos
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
Related Content